Clinical Trial Details
— Status: Completed
Administrative data
NCT number |
NCT04411069 |
Other study ID # |
NP 1336/18 |
Secondary ID |
|
Status |
Completed |
Phase |
Phase 2
|
First received |
|
Last updated |
|
Start date |
February 20, 2019 |
Est. completion date |
March 20, 2021 |
Study information
Verified date |
May 2021 |
Source |
Instituto do Cancer do Estado de São Paulo |
Contact |
n/a |
Is FDA regulated |
No |
Health authority |
|
Study type |
Interventional
|
Clinical Trial Summary
Previous history of nausea and vomiting induced by prior chemotherapy still not included as
predictive factor of postoperative nausea and vomiting, although has been demonstrated that
has influence in postoperative outcome.
The project aims to evaluate the efficacy of a simplified algorithm in prevention
postoperative nausea and vomiting , with pacients with previous history of nausea and
vomiting induced by prior chemotherapy, submitted to medium or large surgery.
Description:
Quasi-experimental study, with evaluation after the application of a specific postoperative
nausea and vomiting prevention algorithm for cancer patients.
The study will be carried out in 2 phases:
Phase 1: Team training. In this phase, a protocol was established for PONV prophylaxis, using
two questions:
1. Patient undergoing chemotherapy before surgery;
2. Patient presented chemotherapy induced nausea and vomiting (CINV).
If the answer is yes to both questions, the anesthetist administers 3 antiemetics (4mg
dexametasone, 4mg ondansetron and 0,625mg droperidol). If the answer is no to one of the
questions, the anesthetist administers 2 antiemetics (4mg dexametasone and 4mg ondansetron);
In this phase, educational measures will be implemented by team meetings and individual
approach of all anesthesiologists at ICESP to present the study project and the algorithm. A
summary of the the study will be sent daily through the social network Whats AppĀ®.
The number of patients was calculated taking into account adherence to the new prophylaxis
protocol for post-operative nausea and vomiting. If we consider an alpha error of 5% and test
power of 80%, to have a NVPO reduction of 41% (current overall incidence) to 25% (incidence
after protocol adherence) in high-risk patients, we need to study 270 patients (135 each
group adherence and non-adherence to the protocol).
Phase 2: Post-training assessment. In the second phase of the study, after the end of the
dissemination of the protocol among doctors, the patients will be evaluated on the first
postoperative day. The following variables were analyzed: sex, race, age, body mass index,
general state of American Society of Anesthesiologist, Apfel scale, type of surgery and
anesthesia, use and type of opioids, history of chemotherapy induced nausea and vomiting,
type of antiemetics used in the operating room and in the first postoperative day, duration
of anesthesia and surgery and nausea and vomiting in 6 and 24 hours after surgery.